Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and ExpansionLOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings mo ...